Allogene Therapeutics
Rengeshbabu Puliyadi is a seasoned professional with extensive experience in quality and regulatory systems within the biopharmaceutical industry. Currently serving as Senior Manager at Allogene Therapeutics since July 2020, Rengeshbabu previously held various technical leadership roles at Gilead Sciences, where responsibilities included implementing Veeva Quality Docs and managing enterprise content management systems. Additional experience includes technical leadership positions at CVS Caremark Corporation, Target, and Amazon.com, focusing on content management applications and system upgrades. Rengeshbabu holds a Master of Computer Applications (MCA) and a Bachelor of Computer Science (BCS) from Madurai Kamaraj University.
This person is not in any teams
This person is not in any offices
Allogene Therapeutics
1 followers
Allogene Therapeutics is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. The goal of our allogeneic cell therapy platform is simple: take the same biological processes that allow the first generation autologous CAR T therapies to deliver breakthrough clinical benefits but eliminate the need to create a personalized therapy for each patient. Instead, we start with T cells from healthy donors, which is intended to allow for creation of inventory for “off-the-shelf” use in patients faster, more reliably, and at greater scale.